Drug intelligence / Profile preview

placebo gel (Sano Chemicals)

Development stage: Unknown
Lead developer: Sano Chemicals
Administration: Topical, Intravaginal

Overview

The placebo gel developed by Sano Chemicals Inc is an inactive control formulation used in clinical trials for the treatment of acute vulvovaginal candidiasis. Specifically utilized in the Phase 2a BLOSSOM study, this water-miscible viscous gel is designed to mimic the physical properties of the active intervention, OCF001 intravaginal gel, but lacks the active antifungal antibiotic component. Its primary purpose is to serve as a comparator to evaluate the safety, tolerability, and therapeutic efficacy of OCF001 in women aged 18 to 65.

Other names: Placebo GelPlacebo (Gel formulation without OCF)

Beyond the preview

Go deeper on placebo gel (Sano Chemicals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo gel (Sano Chemicals).

Explore the full profile